Transcatheter Aortic Valve Implantation Clinical Trial
— Compare-TAVIOfficial title:
Randomized Comparison of Eligible TAVI-valves - Cohort B (Sapien Versus Myval)
The study performs head-to-head comparison of two TAVI-valves: Sapien and Myval.
Status | Recruiting |
Enrollment | 1062 |
Est. completion date | December 31, 2032 |
Est. primary completion date | November 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Patient more than 18 years of age. 2. Patient eligible for at least 2 valves being implanted routinely at the participating center, according to a TAVI heart team conference. 3. The center experience for each of the valves considered should be more than 15 cases a year, and at least 15 valves implanted before a valve can be used in the trial. 4. The center volume should be more than 75 cases a year. 5. The patient has given signed informed consent. 6. TAVI performed via the femoral artery. Exclusion Criteria: 1. Not able to give written inform consent |
Country | Name | City | State |
---|---|---|---|
Denmark | Aarhus University Hospital | Aarhus |
Lead Sponsor | Collaborator |
---|---|
Aarhus University Hospital Skejby | Aalborg University Hospital, Odense University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of patients with MACE (Major Adverse Cardiovascular Events) | Mortality, stroke, moderate/major PVL, moderate/severe aortic device stenosis at 1 year, using VARC-3 criteria | 1 year | |
Secondary | Percentage of patients with MACE | Mortality, stroke, moderate/major paravalvular leakage (PVL), moderate/severe aortic device stenosis at 1 year, using VARC-3 criteria | 30 day, 3-year, 5-year and 10-year | |
Secondary | Percentage death | Mortality | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Percentage of patients with stroke | According to Valve Academic Research Consortium (VARC)-3 criteria | During admission, 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Percentage of patients with moderate or severe paravalvular leakage | Moderate or severe paravalvular leakage according to VARC-3 criteria | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Percentage of patients with moderate/major aortic stenosis | According to VARC-3 criteria | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Percentage of patients with new pacemaker | New Pacemaker after TAVI-procedure | During admission, 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Percentage of patients with major bleeding | Major bleeding according to Bleeding Academic Research Consortium (BARC) type 3 or 5 criteria, resulting in either a drop in Hbg>=1.86 mmol/l or >=2 units of blood transfusion | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Distance in meters during 6-minute walk test | 6-minute walk test | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Percentage of patients with other TAVI-related complications | conversion to open surgery during implantation, unplanned use of cardiopulmonary support (CPS), coronary artery obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade, valve thrombosis, valve embolization, valve migration, need for TAVI-in-TAVI deployment, using VARC-3 criteria | During TAVI-procedure | |
Secondary | Percentage of patients with endocarditis | Endocarditis | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Proportion with successful implantation of the chosen valve. | This means no need for more than 1 TAVI valve, no change to another valve than planned during the procedure because it was impossible to implant the valve planned, and no conversion to surgery or procedure-related death. | During procedure | |
Secondary | Percentage of patients with major vascular access site and access-related complications | According to VARC-3 criteria | During admission and 30-day | |
Secondary | Percentage of patients with valve thrombosis or severe stenosis | Valve thrombosis or severe stenosis confirmed by Echo or HCT | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Percentage of patients with readmission with congestive heart failure | Readmission with congestive heart failure | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Percentage of patients with increase in creatinin level of 100% or more, or dialysis | Increase in renal creatinine level more than to >=200% (AKIN stage 2-3, VARC-3 criteria) or dialysis | during admission and within 30 days | |
Secondary | Percentage of patients with moderate/severe PVL stratified according to level of annular calcium on HCT in three groups | Severity of PVL stratified according to level of annular calcium on HCT (low/medium/high) | 30-day | |
Secondary | Mean Gradient (AO) stratified according to level of annular calcium on HCT in three groups | Gradient (AO) stratified according to level of annular calcium on HCT (low/medium/high) | 30-day | |
Secondary | Percentage of patients with prosthesis-patient mismatch | Prosthesis-patient mismatch (EOA/body surface area). Severe PPM=0.65 cm2/m2. Moderate PPM=0.85 cm2/m2 according to VARC-3 criteria | 30-day, 1-year, 3-year, 5-year, 10-year | |
Secondary | Mean effective orifice area measured by MRI | Effective orifice area measured by MRI in patients participating in MRI-substudy | 30-day | |
Secondary | Percentage of patients with leaflet thickening (hypoattenuated leaflet thickening = HALT) or reduced leaflet motion or thrombus assessed by HCT | Leaflet thickening (hypoattenuated leaflet thickening = HALT) or reduced leaflet motion or thrombus assessed by HCT in patients participating in HCT-substudy | 30-day and 1-year | |
Secondary | Mean volume of aortic regurgitation measured by MRI | Volume of aortic regurgitation measured by MRI in patients participating in MRI-substudy | 30-day | |
Secondary | Other tavi-related complications | Anulus rupture or aortic rupture | 30-day | |
Secondary | AMI | Acute Myocardial Infarction | 30-day, 1-year, 3-year, 5-year and 10-year | |
Secondary | PCI og CABG | Percutaneous Coronary Intervention or coronary artery bypass grafting | 30-day, 1-year, 3-year, 5-year and 10-year | |
Secondary | Reopeation | Reopeation with TAVI, Surgical ortic valve replacement (SAVR) or BAV (Balloon aortic valvuloplasty) according to VARC-3 criteria | 30-day, 1-year, 3-year, 5-year and 10-year | |
Secondary | Afib | Newly diagnosed atrial fibrillation according to VARC-3 criteria | 30-day, 1-year, 3-year, 5-year and 10-year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808907 -
Patient Reported Outcomes (PROMs) in Transcatheter Aortic Valve Implantation (TAVI) Patients
|
||
Recruiting |
NCT05133843 -
Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis
|
N/A | |
Completed |
NCT02976792 -
Effectiveness of the NephroCheck⢠After TAVI
|
||
Enrolling by invitation |
NCT06212050 -
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
|
||
Completed |
NCT04482816 -
Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post-TAVI
|
N/A | |
Not yet recruiting |
NCT05528211 -
Safety and Efficacy of Emergent TAVI in Patients With Severe AS
|
||
Recruiting |
NCT06197503 -
Randomized Study of Physiological vs Right Ventricular Pacing in Patients With Normal Ventricular Function Post TAVI
|
N/A | |
Recruiting |
NCT05804903 -
Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis
|
N/A | |
Recruiting |
NCT03291925 -
Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI
|
N/A | |
Recruiting |
NCT05217888 -
The Sentinel Registry
|
||
Recruiting |
NCT05491070 -
Comparison of Different Vascular Closure Device in TAVI
|
N/A | |
Recruiting |
NCT06189976 -
Rapid Atrial Pacing After TAVI to Predict Pacemaker Implantation
|
N/A | |
Completed |
NCT04921475 -
Renal Regional Oxygen Saturation During Transcatheter Aortic Valve Implantation
|
||
Completed |
NCT03966417 -
Exercise Training After Transcatheter Aortic Valve Implantation
|
N/A | |
Not yet recruiting |
NCT05895097 -
Conventional Versus Left Bundle Branch Pacing in TAVI
|
N/A | |
Not yet recruiting |
NCT05422170 -
HEParin Antagonisation in Transcatheter Aortic Valve Implantation
|
||
Completed |
NCT01539746 -
Transcatheter Aortic Valve Implantation Without Predilation
|
N/A | |
Active, not recruiting |
NCT05478161 -
Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis
|
N/A | |
Recruiting |
NCT02659137 -
HV Electrophysiology Study In Transcatheter Aortic Valve Implantation Patients
|
N/A | |
Completed |
NCT02224066 -
Platelet Reactivity After TAVI: A Multicenter Pilot Study
|
Phase 4 |